DCB vs DES Intervention Clinical Trial for Multivessel Coronary Artery Disease
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov registered a new prospective, multicenter, randomized clinical trial (NCT07539324) comparing drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) against drug-eluting stent-based PCI in patients with multivessel coronary artery disease. The trial will evaluate lesions measuring 2.25 mm to 4.0 mm in diameter using GENOSS DCB and second/third-generation drug-eluting stents.
What changed
NIH ClinicalTrials.gov published a new clinical trial registration for NCT07539324, an investigator-initiated study comparing DCB-based PCI using the GENOSS Paclitaxel-coated balloon catheter against DES-based PCI using second/third-generation drug-eluting stents in patients with multivessel coronary artery disease.
Pharmaceutical companies, medical device manufacturers, and clinical investigators involved in coronary interventions should note this trial's enrollment criteria (lesion diameter 2.25-4.0mm) and interventions as these represent current therapeutic options under clinical evaluation for multivessel disease.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
N/A NCT07539324 Kind: NA Apr 20, 2026
Abstract
This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.
Conditions: Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter), Second, Third Generation Drug-Eluting Coronary Stent System
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.